[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].
Nihon Shokakibyo Gakkai Zasshi
; 109(7): 1186-96, 2012 Jul.
Article
in Ja
| MEDLINE
| ID: mdl-22790623
ABSTRACT
At Nagoya Medical Center, 10 patients co-infected with HIV and HCV received peginterferon α (PEG-IFNα) plus ribavirin therapy. Three of the cases were HCV genotype 1b, 2 cases were HCV 3b, and 1 case each were 2b, 2c, 3a, 4a and 6n. Nine patients received anti HIV therapy from the beginning. In 5 of these patients, anti HIV therapy was modified when PEG-IFNα plus ribavirin treatment was started. Of the above, 7 patients completed the protocol. No patients had severe adverse effects. Sustained virological response was achieved in 1 of 4 (25%) of the patients with genotypes 1 or 4, and in 5 of 6 (83%) of the patients with other genotypes. PEG-IFNα plus ribavirin therapy is considered a safe and efficacious treatment for patients co-infected with HIV and HCV.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ribavirin
/
HIV Infections
/
Interferon-alpha
/
Hepatitis C, Chronic
Type of study:
Evaluation_studies
/
Guideline
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Ja
Journal:
Nihon Shokakibyo Gakkai Zasshi
Year:
2012
Document type:
Article
Affiliation country:
Japan
Country of publication:
JAPAN
/
JAPON
/
JAPÃO
/
JP